The struggle with myopia treatment for American children is a regulatory dilemma. As a medical professional, I've witnessed the frustration of patients and their families who desperately seek effective solutions. The current regulatory landscape poses a significant challenge, leaving many children with myopia without access to potentially life-changing treatments. This is a critical issue that demands attention and action. Democracy thrives in the light of transparency and accountability, and it's time to shed light on this regulatory failure, ensuring that American children receive the care they deserve.
